GlassScriptPhysician profile
Gregory Puglisi
NPI 1225161284
$812,572.79
in general payments reported to CMS, 2019-2025
52 companies · $170K in 2025
The $170K reported for 2025 was more than what 99% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62K · 2020: $35K · 2021: $101K · 2022: $151K · 2023: $138K · 2024: $156K · 2025: $170K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $390K · Food and Beverage: $27K · Travel and Lodging: $25K · Consulting Fee: $15K · Honoraria: $5,400 · Education: $275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $390,156.77 |
| Food and Beverage | $27,473.49 |
| Travel and Lodging | $24,704.70 |
| Consulting Fee | $14,807.74 |
| Honoraria | $5,400.00 |
| Education | $274.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $239,327.85 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Genzyme Corporation | $237,330.74 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $192,247.46 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $70,937.14 | 2019-2025 | Nucala, Trelegy Ellipta |
| Optinose US, INC. | $23,407.63 | 2019-2025 | |
| Pfizer INC. | $13,105.70 | 2019-2025 | |
| Amgen INC. | $8,272.56 | 2021-2025 | Tezspire, Actimmune |
| Organon LLC | $6,652.29 | 2025 | Vtama |
| Biocryst US Sales Co., LLC | $5,779.63 | 2021-2025 | Orladeyo |
| Novartis Pharmaceuticals Corporation | $4,250.58 | 2019-2025 | |
| Dermavant Sciences, INC. | $1,983.51 | 2023-2024 | Vtama |
| Takeda Pharmaceuticals U.S.A., INC. | $1,832.66 | 2020-2025 | Cuvitru, Takhzyro, Eohilia |
| Sanofi-Aventis U.S. LLC | $1,215.98 | 2019-2024 | |
| Abbvie INC. | $813.36 | 2022-2023 | |
| Grifols USA, LLC | $743.26 | 2019-2025 | Xembify, Prolastin-C Liquid |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Puglisi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.